Medspa Inventory Shrinkage: Where It Comes From and How to Stop It

What shrinkage actually is

Inventory shrinkage is the gap between the product you purchased and the product you can account for in visit records. It’s not a line item anywhere in your financials. It doesn’t appear on your P&L. It shows up only when someone reconciles physical inventory against purchase records — and in most medspas, that happens rarely if at all.

The word “shrinkage” carries retail connotations of theft, and while product theft does occur in clinical settings, it accounts for a small fraction of the problem. The majority of shrinkage in a medspa comes from four much more mundane sources — none of which require bad intent, and all of which require operational systems to catch.

The four sources of injectable shrinkage

1. Provider overuse

Provider overuse is when an injector uses more product than was charted, billed, or intended for a visit. This can be deliberate — an injector who is generous with product to improve patient outcomes — or inadvertent, from technique variation or poor vial management.

The problem isn’t generosity. The problem is invisibility. If an injector consistently uses 5 extra units of Botox per appointment and sees 20 patients a week, that’s 100 units per week in product cost that doesn’t appear in any visit record. At $6.50/unit, that’s $650 per week — $33,800 per year — going unreported on a single provider.

Without fractional dosing records at the visit level, you can’t see the variance. Two injectors billing identical services can have dramatically different product consumption — and without tracking, the difference surfaces only as a vague sense that the margins “feel off.”

2. Untracked partial vials

This is the most common source of shrinkage and the hardest to eliminate without the right systems. A 100-unit vial of Botox used across three patients — 40, 35, and 25 units — should account for every unit. In practice, what often happens is the vial gets logged against the first patient and the remaining units are either assumed to be used in subsequent visits without records, or written off as waste when the vial is discarded.

Neither outcome is accurate. The first creates phantom product that appears in inventory but has no cost assigned to future visits. The second creates a waste write-off that buries a real cost without any traceability.

Partial vial management requires a system that keeps a vial open and tracked — with its remaining volume, its lot number, and its cost per unit — until it is genuinely exhausted. That’s not possible in a spreadsheet unless someone is updating it after every single appointment.

3. Expired product

Expired product is a 100% loss. You paid for it. You can’t use it. It generates no revenue and produces no visit record. It just disappears from inventory as a write-off.

The cause is almost always the same: FEFO rotation wasn’t enforced. A newer lot got opened while an older lot aged toward expiration in the back of the fridge. By the time the older lot was discovered, it was too late.

In a medspa carrying $30,000 in injectable inventory at any given time, even 3% expiration is $900 in pure waste per month — $10,800 per year. Most practices discover expired product during physical counts, record it as a loss, and move on without any analysis of which lots were affected or why the rotation failed.

4. Unrecorded usage

This category covers everything that consumes product without a corresponding visit record: samples given to prospective patients, touch-up appointments that weren’t logged, corrections for a patient who had a suboptimal result, comp’d services for staff or VIP clients, and product used for training or demonstrations.

None of these are inherently wrong. Samples build new patients. Touch-ups build loyalty. Staff treatments are a legitimate benefit. The problem is when product is consumed without any log — no reason code, no quantity, no cost record.

Unrecorded usage doesn’t mean the product is being stolen. It means it’s being used in ways that don’t generate a COGS record, which means the usage appears as shrinkage in any reconciliation even though it served a legitimate purpose.

What shrinkage actually costs at scale

The math is straightforward once you run it. For a medspa spending $600,000 per year on product:

These numbers don’t appear as a loss anywhere in most practices’ financials. They appear as lower-than-expected margins with no explanation. Revenue looks fine. The bank account doesn’t. The gap is shrinkage — and without tracking systems, there’s no way to know how large it is.

How to calculate your current shrinkage rate

The formula: (expected inventory − physical count) ÷ total product purchased × 100

Expected inventory = opening stock value + all purchases during the period − all recorded usage during the period.

The catch: if your recorded usage is unreliable — averaged, estimated, or missing fractional dosing data — the expected inventory number is unreliable too, and the calculation produces a number that sounds precise but isn’t.

This is why shrinkage calculation and visit-level tracking have to be built together. The shrinkage number is only as good as the usage records feeding into it.

The four controls that actually reduce shrinkage

Fractional dosing records at every visit

Every unit drawn from a vial gets recorded — not rounded, not estimated, not assigned to a waste bucket. The visit record carries exactly what was used, from which lot, at what cost. Partial vials stay open and tracked until genuinely empty.

This is the single highest-impact control because it eliminates the largest source of shrinkage — untracked partial vials — and simultaneously makes provider variance visible.

FEFO rotation enforced by software

When a visit is being recorded, the system identifies the correct lot to use automatically — the one expiring soonest — rather than relying on whoever is prepping the treatment room to check dates. Expiration alerts fire in advance, not on the day the lot expires.

Manual FEFO fails because it requires memory and discipline at the point of prep. Software-enforced FEFO fails rarely, because the correct lot is presented by default.

A logging policy for all non-visit product usage

Samples, touch-ups, corrections, staff treatments, and comp’d services all consume product. Each one should carry a log entry with a quantity, a lot, and a reason code — even if no revenue was generated.

This doesn’t eliminate those activities. It makes them visible. When non-visit usage is logged with reason codes, shrinkage reconciliation can separate intentional give-aways from unexplained gaps. One is policy. The other is a problem.

Reconciliation by lot, not by month-end total

Month-end reconciliation tells you the total variance. Lot-level reconciliation tells you which lot, which provider, which time period, and which service drove the variance.

The difference in actionability is enormous. A month-end total of $3,200 in shrinkage produces a meeting where everyone shrugs. A lot-level reconciliation that shows Lot 24B7 lost 18 units in the third week of the month — during a period when one provider was the only one drawing from it — produces a conversation with a specific person about a specific behavior.

The honest summary

Shrinkage is not a character problem. It’s a visibility problem. Most of it comes from normal clinical activity — partial vials, variation in technique, products used outside of visit records — that simply isn’t being captured. The practices with the lowest shrinkage rates aren’t the ones with the most rigorous staff; they’re the ones with the most rigorous systems.

Systems that record fractional dosing, enforce FEFO, log all product usage, and reconcile at the lot level don’t eliminate shrinkage entirely — waste and technique variation are always present. But they make the gap visible, quantified, and attributable. That’s the difference between shrinkage as a vague problem and shrinkage as a number you can actually do something about.